L'Institut de Cancérologie de Lorraine (ICL) Alexis Vautrin
Welcome,         Profile    Billing    Logout  
 2 Trials 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
GEOFFROIS, Lionnel
CABRAMET, NCT03967522: Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases

Completed
2
26
Europe
Cabozantinib
Centre Leon Berard
Metastatic Renal Cell Carcinoma
10/24
11/24
TAS-120-203, NCT04601857 / 2020-000945-15: Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma

Active, not recruiting
2
43
Europe, US
futibatinib and pembrolizumab (KEYTRUDA®)), TAS120 and MK-3475-B04
Taiho Oncology, Inc., Merck Sharp & Dohme LLC
Advanced and Metastatic Urothelial Cancer
03/24
08/25
PAXIPEM, NCT05096390 / 2021-001065-21: Axitinib +/- Pembrolizumab in First Line Treatment of mPRCC

Recruiting
2
72
Europe
Axitinib Oral Tablet [Inlyta], Pembrolizumab Injection [Keytruda]
Centre Leon Berard, Pfizer
Papillary Renal Cell Carcinoma Type 2
10/24
06/26
CARPACCIO, NCT06725368: Carboplatin + Paclitaxel + Cetuximab (PCC) After Failure of Pembrolizumab +/- First-line Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Recruiting
2
46
Europe
PCC
Institut de cancérologie Strasbourg Europe
Head and Neck Cancer
12/27
12/31
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
GEOFFROIS, Lionnel
CABRAMET, NCT03967522: Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases

Completed
2
26
Europe
Cabozantinib
Centre Leon Berard
Metastatic Renal Cell Carcinoma
10/24
11/24
TAS-120-203, NCT04601857 / 2020-000945-15: Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma

Active, not recruiting
2
43
Europe, US
futibatinib and pembrolizumab (KEYTRUDA®)), TAS120 and MK-3475-B04
Taiho Oncology, Inc., Merck Sharp & Dohme LLC
Advanced and Metastatic Urothelial Cancer
03/24
08/25
PAXIPEM, NCT05096390 / 2021-001065-21: Axitinib +/- Pembrolizumab in First Line Treatment of mPRCC

Recruiting
2
72
Europe
Axitinib Oral Tablet [Inlyta], Pembrolizumab Injection [Keytruda]
Centre Leon Berard, Pfizer
Papillary Renal Cell Carcinoma Type 2
10/24
06/26
CARPACCIO, NCT06725368: Carboplatin + Paclitaxel + Cetuximab (PCC) After Failure of Pembrolizumab +/- First-line Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Recruiting
2
46
Europe
PCC
Institut de cancérologie Strasbourg Europe
Head and Neck Cancer
12/27
12/31

Download Options